Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 14/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23198768 | 0.96 | PARP1 (0.40) | PARP1TNKS2PARP2RAF1BRAF | |
| SCHEMBL23202653 | 0.93 | RAF1 (0.40) | PARP1TNKS2PARP2RAF1BRAF | |
| SCHEMBL23202610 | 0.85 | PARP1 (0.43) | PARP1TNKS2PARP2RAF1BRAF | |
| SCHEMBL23198767 | 0.84 | PARP1 (0.44) | PARP1TNKS2PARP2RAF1BRAF | |
| SCHEMBL23202652 | 0.81 | PARP1 (0.43) | PARP1TNKS2PARP2RAF1BRAF | |
| SCHEMBL25314059 | 0.80 | USP30 (0.42) | PARP1TNKS2PARP2PDCD1CD274 | |
| SCHEMBL30389164 | 0.80 | USP30 (0.42) | PARP1TNKS2PARP2PDCD1CD274 | |
| SCHEMBL25314286 | 0.79 | PDCD1 (0.42) | PDCD1CD274USP30MAPK8 | |
| SCHEMBL30389125 | 0.79 | PDCD1 (0.42) | PDCD1CD274USP30MAPK8 | |
| SCHEMBL24722483 | 0.78 | PDCD1 (0.42) | PARP1TNKS2PARP2RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402917-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2022-12-22 | — | — | US | disclosed |
| EP-4043461-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021063404-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402917-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | CD274, PDCD1, PDCD1LG2 | PARP1 342/4885TNKS2 1486/4885PARP2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.